NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Global Market for Pain Management Drugs and Devices
http://www.reportlinker.com/p01080064/The-Global-Market-for-Pain-Management-Drugs-and-Devices.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine
INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY SCOPE AND FORMATThe report identifies two general segments of pain management:- Pharmaceuticals.- Devices.
Within the pharmaceuticals segment several sub-segments are discussed in detail including:
- Narcotic pain management.
- Non-narcotic pain management.
- Antimigraine treatments.
- Anesthetics.
- Other drugs (including fibromyalgia treatments).
The device segment covers several product lines and specifically targets the largest product segments including:- TENS and neuromuscular stimulators.- Spinal cord stimulators.- Other products (including electromagnetic therapies and other treatments).
Each market segment provides detailed information based on product categories, product use, forecasts, and competitive analyses.
METHODOLOGY
Market data for this report pertains to the global market and uses U.S. dollars at the manufacturers' level. The base year of the report is 2012, with historical data provided for 2008 through 2011, and forecast data provided through 2017. Historical, base year and forecast data are provided for each market segment of the report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, and current product growth, etc. Competitor market share estimates are provided for each market segment for the 2012 base year.
ANALYST CREDENTIALS
Melissa Elder is an experienced healthcare market analyst specializing in prescription and over-the-counter pharmaceuticals, medical devices, and emerging healthcare technologies. Ms. Elder has nearly 20 years of experience in the healthcare industry, specializing in market research for the past 14 years. This experience has given her substantial insight into pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.
REPORT HIGHLIGHTS
This report provides:- An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.- Analyses of global market trends, with data from 2012, and projections of compound annual growth rates (CAGRs) through 2017.- Examination of product categories, use of products, and the competitive landscape.- Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.- Discussion of new regulatory requirements.- Comprehensive company profiles of major players in the industry.
TABLE OF CONTENTS
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE AND FORMAT 1
METHODOLOGY 2
ANALYST CREDENTIALS 2
RELATED BCC STUDIES 2
BCC ON-LINE SERVICES 2
DISCLAIMER 3
CHAPTER 2 SUMMARY 5OVERVIEW 5GENERAL PAIN TERMINOLOGY 5MAJOR MARKETS SUMMARY 6SUMMARY TABLE GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICESMARKET, 2012 AND 2017 ($ MILLIONS) 7SUMMARY FIGURE GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICESMARKET, 2012 AND 2017 ($ MILLIONS) 7MARKET TRENDS 7UNDER-TREATMENT ISSUES 8PROFESSIONAL PAIN TREATMENT ISSUES 8ACCESS TO CARE 8GLOBAL HEALTHCARE SYSTEMS 8FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES 8DRUG DELIVERY SYSTEMS 9COMPETITORS 9
CHAPTER 3 INDUSTRY OVERVIEW 11
HISTORY OF PAIN AND PAIN TREATMENT 11
THE PERCEPTION OF PAIN 12
Types of Pain 12
Acute Pain 12
Chronic Pain 13
ASSESSMENT OF PAIN 13
Subjective 13
Objective 13
TABLE 1 OBJECTIVE SIGNS OF PAIN 14
HOW PAIN IS DIAGNOSED 14
THERMOGRAPHY 15
HOW PAIN IS TREATED 15
FIGURE 1 PAIN-MANAGEMENT TECHNIQUES 15
DEMOGRAPHICS AND AGING POPULATIONS 20
Global Demographics 20
TABLE 2 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE
GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS) 21
FIGURE 2 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED
YEARS, 2000-2030 (MILLIONS) 21
TABLE 3 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS) 22
FIGURE 3 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015
(MILLIONS) 22
Global Life Expectancy 23
TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
(YEARS) 23
FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
(YEARS) 24
GLOBAL PAIN MANAGEMENT 24
FIGURE 5 GLOBAL CANCER DEATHS BY TYPE, 2008 (THOUSANDS) 25
INCIDENCE OF PAIN 26
PREVALENCE OF PAIN 26
Severe Headache or Migraine, Low Back, and Neck Pain 26
TABLE 5 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG
ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%) 26
FIGURE 6 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG
ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%) 27
Orthopedic Pain 28
Osteoarthritis 28
Rheumatoid Arthritis 28
Ankylosing Spondylitis 28
Fibromyalgia 29
Gout 29
Scleroderma 29
Lupus 29
Bursitis and Tendonitis 29
Osteoporosis 30
Low Bone Mass 30
TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE
WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE, 2008-2010 30
FIGURE 7 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE
WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE 2008–2010 31
Cancer Pain 31
FIGURE 8 CAUSES OF CANCER PAIN 32
Pain Management in Cancer 33
TABLE 7 CANCER PAIN MEDICATION 33
Description of Some of Key Medications for Cancer Pain Control 34
Morphine 34
Fentanyl 34
Hydromorphone 34
Methadone 34
Buprenorphine 35
Oxycodone 35
Tapentadol 35
HIV/AIDS Related Pain 35
TABLE 8 ESTIMATED HIV REPORTED CASES BY REGION, 2011 36
FIGURE 9 ADULT PREVALENCE RATE, 2011 (%) 36
Burn Pain 36
Burn Classifications 37
TABLE 9 BURN CLASSIFICATIONS 37
Stages of Burn Healing 38
Challenges Associated with Burn Pain 39
Burn Pain Management 39
FIGURE 10 BURN PAIN MANAGEMENT APPROACH 40
Dental Pain 40
Treatment for Dental Pain 41
Obstetrics Pain 41
TABLE 10 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES 42
FIGURE 11 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES 42
Surgical pain 42
U.S. Surgical Procedures 43
TABLE 11 U.S. SURGICAL PROCEDURES 44
Global Surgical Procedures 44
TABLE 12 SELECT SURGICAL PROCEDURES FOR GERMANY, UNITED KINGDOM, AND
FRANCE 45
GENDER AND PAIN 45
TABLE 13 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*
(THOUSANDS) 46
FIGURE 12 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*
(THOUSANDS) 47
OTHER INFLUENCES DETERMINING HOW PAIN IS FELT AMONG INDIVIDUALS 47
Objective Pain Measurement 48
PEDIATRIC PAIN 48
CHAPTER 4 INDUSTRY TRENDS 51OVERVIEW 51UNDERTREATMENT ISSUES 51TREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENT 53TABLE 14 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECTREGION/COUNTRY 55PRESCRIPTION DRUG MONITORING PROGRAMS 56TABLE 15 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES AND CLIENTS, 2000–2010 56FIGURE 13 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES, 2000–2010 56FIGURE 14 TOTAL NUMBER OF ABUSE TREATMENT CLIENTS, 2000–2010 57TABLE 16 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS 58TABLE 17 STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS 58TABLE 18 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHERCONTACT INFORMATION 60TABLE 19 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT, BYREQUIRING STATE 73ACCESS TO CARE 73PHYSICIAN TO PATIENT RATIOS 74TABLE 20 PHYSICIANS PER 1,000 POPULATION BY YEAR AND COUNTRY (THOUSANDS) 74FIGURE 15 PHYSICIANS PER 1,000 POPULATION BY COUNTRY, 2010* 75TABLE 21 NUMBER OF PHYSICIAN PER 100,000 RESIDENT POPULATION, UNITED STATES,2009 76FIGURE 16 NUMBER OF PHYSICIANS PER 100,000 RESIDENT POPULATION, UNITED STATES2009 76ACCESS TO PALLIATIVE CARE 77AVAILABILITY OF MEDICATIONS 78TABLE 22 AVAILABILITY OF INJECTABLE MORPHINE BY COUNTRY 78TABLE 23 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS BY COUNTRY 79GOVERNMENT RESTRICTIONS AND SUPPORT 80Drug Supply 80Single Convention on Narcotic Drugs 81Government Subsidies 81PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD 81TABLE 24 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50(2000) 82RISING HEALTHCARE COSTS 83TABLE 25 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980 TO 2010 83AVERAGE LENGTH OF STAY 83TABLE 26 HOSPITAL USAGE STATISTICS, AVERAGE 2000-2010 (DAYS) 84FIGURE 17 HOSPITAL USAGE STATISTICS (DAYS) 84MANAGED CARE PAIN MANAGEMENT ISSUES 85FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES 85NEW RULES AND LEGISLATION 86Risk Evaluation and Mitigation Strategy (REMS) 86TABLE 27 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIREDTO HAVE AN OPIOID REMS, BRAND NAME PRODUCTS 86TABLE 28 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIREDTO HAVE AN OPIOID REMS, GENERIC NAME PRODUCTS 87TABLE 29 LIST OF TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTSREQUIRED TO HAVE TIRF REMS ACCESS PROGRAM 88Acetaminophen and FDA Changes 88TABLE 30 LIST OF MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS 89DRUG DELIVERY SYSTEMS 90ORAL AND EXTENDED RELEASE 90TOPICAL AND TRANSDERMAL 90INTRAVENOUS 91INTRANASAL 91PATIENT-CONTROLLED ANALGESIA 91IONTOPHORESIS 91TABLE 31 ADVANTAGES OF IONTOPHORETIC DRUG DELIVERY 92ELECTROMECHANICAL TRANSPORT 92
CHAPTER 5 TREATING PAIN 94
PHARMACEUTICAL PAIN MANAGEMENT 94
PRESCRIPTION PAIN MANAGEMENT PRODUCTS 94
TABLE 32 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-OCTOBER 2012 94
Analgesic Drugs 96
Non-Narcotic 97
Narcotic 97
Full and Partial Agonists 99
Agonist-Antagonists 100
Nonsteroid Anti-inflammatory Drugs 101
Anti-migraine Drugs 102
Antidepressant, Anticonvulsants, and Other Pain Relieving Drugs 103
ANESTHETICS 103
General 103
TABLE 33 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS 104
Local/Regional 105
Topical 105
OVER-THE-COUNTER PAIN MANAGEMENT PRODUCTS 105
ANALGESIC DRUGS 105
TABLE 34 ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS 106
NONSTEROID ANTI-INFLAMMATORY DRUGS 106
Aspirin Products and Aspirin Combination Products 107
TABLE 35 ASPIRIN AND ASPIRIN COMBINATION PRODUCTS 107
Ibuprofen and Ibuprofen Combination Products 107
TABLE 36 IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS 108
Ketoprofen Products 108
TABLE 37 KETOPROFEN PRODUCTS 108
Naproxen Compounds 108
TABLE 38 OTC NONSTEROID ANTI-INFLAMMATORIES 109
ANTI-MIGRAINE DRUGS 109
TABLE 39 ANTI-MIGRAINE PRODUCTS 109
TOPICAL ANESTHETIC DRUGS 109
TABLE 40 TOPICAL ANESTHETIC PRODUCTS 110
PAIN MANAGEMENT DEVICES 110
TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS 111
PAIN TEM 112
SPINAL CORD STIMULATORS 112
NEUROMUSCULAR STIMULATORS 113
OTHER PAIN MANAGEMENT DEVICES 114
Electromagnetic Therapy 115
PAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY, FLUOROSCOPY 116
ALTERNATIVE METHODS OF PAIN MANAGEMENT 116
PSYCHOLOGICAL THERAPIES 118
Biofeedback 118
Hypnosis 118
Behavior Modification/Operant Conditioning 119
Relaxation and Stress Management Training 119
Imagery 120
Autogenic Training 120
Psychosocial Interventions 120
Distraction and Reframing 120
PHYSICAL THERAPIES 121
Ice 121
Warm Bath 121
Massage 121
Joint Mobilization 122
Manipulation 122
Traction 122
Acupuncture/Acupressure 122
Laser Therapy 123
Surgery 124
Radiation Therapy 124
Radio-Frequency Neuroablation, Epiduroscopy 124
TABLE 41 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY
AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,
2002-2012 (THOUSANDS OF PEOPLE) 125
FIGURE 18 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY
AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,
2002-2012 (THOUSANDS OF PEOPLE) 125
PAIN MANAGEMENT SERVICES AND ORGANIZATIONS 126
HOME CARE 126
HOSPICE 127
FIGURE 19 TOTAL HOSPICE PATIENTS SERVED BY YEAR, 2006-2010 (TOTAL PATIENTS
SERVED, ESTIMATE) 128
TABLE 42 HOSPICE STATISTICS, PATIENTS BY CHARACTERISTICS, 2009 AND 2010 (% OF
TOTAL) 129
FIGURE 20 TOTAL HOSPICE PATIENTS BY GENDER, 2009 AND 2010 (% OF TOTAL) 129
FIGURE 21 TOTAL HOSPICE PATIENTS BY AGE, 2009 AND 2010 (% OF TOTAL) 130
TABLE 43 HOSPICE STATISTICS, PATIENTS BY PRIMARY DIAGNOSIS (% OF TOTAL) 130
FIGURE 22 TOTAL HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009 AND 2010 (% OF
TOTAL) 131
NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION 132
TABLE 44 NHPCO COMMITTEES AND TASK FORCES 132
HOSPITALS 133
TABLE 45 ESTIMATED NUMBER OF REGISTERED HOSPITALS BY SELECTED COUNTRY, 2010
ESTIMATES 133
TABLE 46 TOTAL NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2010 134
Hospital Departments 134
Emergency Rooms (ER) 134
Critical-Care Units (CCU) 134
PAIN CLINICS 135
SKILLED NURSING FACILITIES 136
CHAPTER 6 PRESCRIPTION PAIN MANAGEMENT MARKET SIZE AND ANALYSIS 138TOTAL MARKET 138PRESCRIPTION PAIN MARKETS BY PRODUCT TYPE 138TABLE 47 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET ATMANUFACTURERS' SALES LEVELS, THROUGH 2017 ($ MILLIONS) 139FIGURE 23 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET ATMANUFACTURERS' SALES LEVELS, 2008-2017 ($ MILLIONS) 139NARCOTIC ANALGESICS 139NON-NARCOTIC ANALGESICS 140ANTIMIGRAINE AGENTS 140ANESTHETICS 140OTHER DRUG CLASSES 141MARKET PARTICIPANTS 141NARCOTIC/NON-NARCOTIC MARKET SHARE 141TABLE 48 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKETSHARE BY REVENUE, 2012 ($ MILLIONS) 142FIGURE 24 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKETSHARE BY REVENUE, 2012 ($ MILLIONS) 142MIGRAINE TREATMENT MARKET SHARE 142TABLE 49 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BYREVENUE, 2012 ($ MILLIONS/%) 143FIGURE 25 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BYREVENUE, 2012 (%) 144ANESTHETIC MARKET SHARE 144TABLE 50 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,2012 ($ MILLIONS) 145FIGURE 26 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,2012 (%) 145FUTURE MARKET ANALYSIS 145
CHAPTER 7 PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSIS 147
TOTAL PAIN MANAGEMENT DEVICE MARKET 147
PAIN MARKETS BY PRODUCT TYPE 147
TABLE 51 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, THROUGH
2017 ($ MILLIONS) 148
FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, 2008-2017
($ MILLIONS) 148
SPINAL CORD STIMULATORS 148
NEUROSTIMULATOR/TENS UNITS 149
OTHER PAIN TREATMENT DEVICES 149
MARKET PARTICIPANTS 149
NEUROMUSCULAR STIMULATOR/TENS MARKET SHARE 149
TABLE 52 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY
DEVICES—MANUFACTURER MARKET SHARE, 2012 ($ MILLIONS) 150
FIGURE 28 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY
DEVICES—MANUFACTURER MARKET SHARE, 2012 (%) 150
SPINAL CORD STIMULATOR MARKET SHARE 150
TABLE 53 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 ($
MILLIONS) 151
FIGURE 29 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 (%) 151
FUTURE MARKET ANALYSIS 151
CHAPTER 8 TOTAL MARKET SUMMARY 153TOTAL PAIN MANAGEMENT MARKET 153TABLE 54 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,THROUGH 2017 ($ MILLIONS) 153FIGURE 30 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,2008-2017 ($ MILLIONS) 153MARKET PERCENTAGE BY PRODUCT TYPE 154TABLE 55 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BYSEGMENT, 2012 (%/$ MILLIONS) 154FIGURE 31 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BYSEGMENT, 2012 (%) 154MARKETS BY WORLD REGION 155TABLE 56 DISTRIBUTION OF GLOBAL PAIN MANAGEMENT REVENUES BY REGION, 2012(%/$ MILLIONS) 156FIGURE 32 PERCENTAGE DISTRIBUTION OF GLOBAL PAIN MANAGEMENT SHARES BYREGION, 2012 (%) 156
CHAPTER 9 INDUSTRY DEVELOPMENTS 158
TIMELINE OF RECENT EVENTS AND DEVELOPMENTS 158
THE PIPELINE 159
TABLE 57 SELECTED PAIN-MANAGEMENT DRUG PIPELINES 159
NEW DEVELOPMENTS IN BREAKTHROUGH CANCER PAIN 162
NEW DEVELOPMENTS IN TREATING NEUROPATHIC PAIN 162
DEVELOPMENTS IN OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCE 163
FUTURE OF PAIN RESEARCH 164
PATIENT OUTCOMES RESEARCH 166
SELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCES 166
JANUARY-OCTOBER 2012 166
2000-2011 167
DRUG PATENTS FOR SELECTED THERAPIES 167
TABLE 58 U.S. PATENT EXPIRATION DATES FOR SELECT PAIN DRUGS 167
IMPACT OF GENERIC PARTICIPATION 168
TABLE 59 FIRST TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS,
JANUARY 2004-OCTOBER 2012 169
CHAPTER 10 COMPANY PROFILES 174PHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERS 174ABBOTT LABORATORIES 174ASTRAZENECA 174BAXTER INTERNATIONAL INC. 175DJO GLOBAL, INC. 175ELI LILLY & CO. 175ENDO PHARMACEUTICALS, INC. 176GLAXOSMITHKLINE 176JOHNSON & JOHNSON 177MEDTRONIC, INC. 178MERCK & CO. INC. 178NOVARTIS INTERNATIONAL AG 179PFIZER 179PURDUE PHARMACEUTICALS LP 180ST. JUDE MEDICAL, INC. 180
CHAPTER 11 APPENDIX I: SELECTED PAIN MANAGEMENT CLINICS-UNITED STATES-BY
STATE 183
ALABAMA PAIN CLINICS 183
CALIFORNIA PAIN CLINICS 184
COLORADO PAIN CLINICS 192
DELAWARE PAIN CLINICS 193
FLORIDA PAIN CLINICS 193
HAWAII PAIN CLINICS 199
IOWA PAIN CLINICS 199
MAINE PAIN CLINICS 200
NEVADA PAIN CLINICS 200
OREGON PAIN CLINICS 201
PENNSYLVANIA PAIN CLINICS 202
RHODE ISLAND PAIN CLINICS 205
SOUTH DAKOTA PAIN CLINICS 205
TEXAS PAIN CLINICS 206
WASHINGTON PAIN CLINICS 208
CHAPTER 12 APPENDIX II: GLOBAL SELECTED PAIN MANAGEMENT CLINICS, BY COUNTRY 212ARGENTINA PAIN CLINICS 212AUSTRALIA PAIN CLINICS 213BRAZIL PAIN CLINICS 214GERMANY PAIN CLINICS 215INDIA PAIN CLINICS 215ITALY PAIN CLINICS 218SINGAPORE PAIN CLINICS 218UNITED KINGDOM PAIN CLINICS 219CHAPTER 13 APPENDIX III: U.S. PAIN SOCIETIES AND ASSOCIATIONS 222
CHAPTER 14 APPENDIX IV: INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONS 224
CHAPTER 15 APPENDIX V: COMPANY NAMES AND ADDRESSES 226PAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERS 226
LIST OF TABLES
2012 AND 2017 ($ MILLIONS) 7
TABLE 1 OBJECTIVE SIGNS OF PAIN 14
TABLE 2 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE
GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS) 21
TABLE 3 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS) 22
TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
(YEARS) 23
TABLE 5 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG
ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%) 26
TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE
WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE, 2008-2010 30
TABLE 7 CANCER PAIN MEDICATION 33
TABLE 8 ESTIMATED HIV REPORTED CASES BY REGION, 2011 36
TABLE 9 BURN CLASSIFICATIONS 37
TABLE 10 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES 42
TABLE 11 U.S. SURGICAL PROCEDURES 44
TABLE 12 SELECT SURGICAL PROCEDURES FOR GERMANY, UNITED KINGDOM, AND
FRANCE 45
TABLE 13 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*
(THOUSANDS) 46
TABLE 14 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT
REGION/COUNTRY 55
TABLE 15 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES AND CLIENTS, 2000–2010 56
TABLE 16 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS 58
TABLE 17 STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS 58
TABLE 18 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER
CONTACT INFORMATION 60
TABLE 19 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT, BY
REQUIRING STATE 73
TABLE 20 PHYSICIANS PER 1,000 POPULATION BY YEAR AND COUNTRY (THOUSANDS) 74
TABLE 21 NUMBER OF PHYSICIAN PER 100,000 RESIDENT POPULATION, UNITED STATES,
2009 76
TABLE 22 AVAILABILITY OF INJECTABLE MORPHINE BY COUNTRY 78
TABLE 23 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS BY COUNTRY 79
TABLE 24 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50
(2000) 82
TABLE 25 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980 TO 2010 83
TABLE 26 HOSPITAL USAGE STATISTICS, AVERAGE 2000-2010 (DAYS) 84
TABLE 27 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIRED
TO HAVE AN OPIOID REMS, BRAND NAME PRODUCTS 86
TABLE 28 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIRED
TO HAVE AN OPIOID REMS, GENERIC NAME PRODUCTS 87
TABLE 29 LIST OF TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED
TO HAVE TIRF REMS ACCESS PROGRAM 88
TABLE 30 LIST OF MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS 89
TABLE 31 ADVANTAGES OF IONTOPHORETIC DRUG DELIVERY 92
TABLE 32 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-OCTOBER 2012 94
TABLE 33 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS 104
TABLE 34 ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS 106
TABLE 35 ASPIRIN AND ASPIRIN COMBINATION PRODUCTS 107
TABLE 36 IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS 108
TABLE 37 KETOPROFEN PRODUCTS 108
TABLE 38 OTC NONSTEROID ANTI-INFLAMMATORIES 109
TABLE 39 ANTI-MIGRAINE PRODUCTS 109
TABLE 40 TOPICAL ANESTHETIC PRODUCTS 110
TABLE 41 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY AND
ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY, 2002-2012
(THOUSANDS OF PEOPLE) 125
TABLE 42 HOSPICE STATISTICS, PATIENTS BY CHARACTERISTICS, 2009 AND 2010 (% OF
TOTAL) 129
TABLE 43 HOSPICE STATISTICS, PATIENTS BY PRIMARY DIAGNOSIS (% OF TOTAL) 130
TABLE 44 NHPCO COMMITTEES AND TASK FORCES 132
TABLE 45 ESTIMATED NUMBER OF REGISTERED HOSPITALS BY SELECTED COUNTRY, 2010
ESTIMATES 133
TABLE 46 TOTAL NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2010 134
TABLE 47 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT
MANUFACTURERS' SALES LEVELS, THROUGH 2017 ($ MILLIONS) 139
TABLE 48 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET SHARE
BY REVENUE, 2012 ($ MILLIONS) 142
TABLE 49 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY
REVENUE, 2012 ($ MILLIONS/%) 143
TABLE 50 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE, 2012
($ MILLIONS) 145
TABLE 51 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, THROUGH
2017 ($ MILLIONS) 148
TABLE 52 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY
DEVICES—MANUFACTURER MARKET SHARE, 2012 ($ MILLIONS) 150
TABLE 53 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 ($
MILLIONS) 151
TABLE 54 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,
THROUGH 2017 ($ MILLIONS) 153
TABLE 55 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY
SEGMENT, 2012 (%/$ MILLIONS) 154
TABLE 56 DISTRIBUTION OF GLOBAL PAIN MANAGEMENT REVENUES BY REGION, 2012 (%/$
MILLIONS) 156
TABLE 57 SELECTED PAIN-MANAGEMENT DRUG PIPELINES 159
TABLE 58 U.S. PATENT EXPIRATION DATES FOR SELECT PAIN DRUGS 167
TABLE 59 FIRST TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS,
JANUARY 2004-OCTOBER 2012 169
LIST OF FIGURES
MARKET, 2012 AND 2017 ($ MILLIONS) 7
FIGURE 1 PAIN-MANAGEMENT TECHNIQUES 15
FIGURE 2 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED
YEARS, 2000-2030 (MILLIONS) 21
FIGURE 3 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015
(MILLIONS) 22
FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
(YEARS) 24
FIGURE 5 GLOBAL CANCER DEATHS BY TYPE, 2008 (THOUSANDS) 25
FIGURE 6 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG
ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%) 27
FIGURE 7 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE
WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE 2008–2010 31
FIGURE 8 CAUSES OF CANCER PAIN 32
FIGURE 9 ADULT PREVALENCE RATE, 2011 (%) 36
FIGURE 10 BURN PAIN MANAGEMENT APPROACH 40
FIGURE 11 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES 42
FIGURE 12 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*
(THOUSANDS) 47
FIGURE 13 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES, 2000–2010 56
FIGURE 14 TOTAL NUMBER OF ABUSE TREATMENT CLIENTS, 2000–2010 57
FIGURE 15 PHYSICIANS PER 1,000 POPULATION BY COUNTRY, 2010* 75
FIGURE 16 NUMBER OF PHYSICIANS PER 100,000 RESIDENT POPULATION, UNITED STATES
2009 76
FIGURE 17 HOSPITAL USAGE STATISTICS (DAYS) 84
FIGURE 18 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY
AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY,
2002-2012 (THOUSANDS OF PEOPLE)
125
FIGURE 19 TOTAL HOSPICE PATIENTS SERVED BY YEAR, 2006-2010 (TOTAL PATIENTS
SERVED, ESTIMATE) 128
FIGURE 20 TOTAL HOSPICE PATIENTS BY GENDER, 2009 AND 2010 (% OF TOTAL) 129
FIGURE 21 TOTAL HOSPICE PATIENTS BY AGE, 2009 AND 2010 (% OF TOTAL) 130
FIGURE 22 TOTAL HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009 AND 2010 (% OF TOTAL) 131
FIGURE 23 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT
MANUFACTURERS' SALES LEVELS, 2008-2017 ($ MILLIONS) 139
FIGURE 24 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET
SHARE BY REVENUE, 2012 ($ MILLIONS) 142
FIGURE 25 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY
REVENUE, 2012 (%) 144
FIGURE 26 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE,
2012 (%) 145
FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, 2008-2017 ($
MILLIONS) 148
FIGURE 28 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY
DEVICES—MANUFACTURER MARKET SHARE, 2012 (%) 150
FIGURE 29 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 (%) 151
FIGURE 30 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE,
2008-2017 ($ MILLIONS) 153
FIGURE 31 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY
SEGMENT, 2012 (%) 154
FIGURE 32 PERCENTAGE DISTRIBUTION OF GLOBAL PAIN MANAGEMENT SHARES BY
REGION, 2012 (%) 156
To order this report:General_Medicine_and_Specialty_Medicine Industry: The Global Market for Pain Management Drugs and Devices
Contact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article